GSK and development partner Ionis reported positive top-line results from two pivotal Phase 3 studies of bepirovirsen, an antisense oligonucleotide aimed at functional cure for chronic hepatitis B. The companies said the trials met their primary endpoints and that global regulatory submissions are planned. The data cover over 1,800 patients across 29 countries, according to company releases, and mark a potential shift from lifelong viral suppression to a time‑limited therapy.